While it has been primarily studied in HER2-amplified breast cancer, it has also been investigated in patients with advanced-stage NSCLC, including those with HER2 mutations and HER2 overexpression [80,81,82,83,84,85,86,87]. The gene discussed is ERBB2; the disease is breast carcinoma.